Condition
Non Alcoholic Steatohepatitis (NASH)
Total Trials
5
Recruiting
0
Active
0
Completed
2
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 55/100
Termination Rate
40.0%
2 terminated out of 5 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
150%
3 of 2 completed with results
Key Signals
3 with results50% success
Data Visualizations
Phase Distribution
5Total
P 2 (3)
P 3 (2)
Trial Status
Terminated2
Completed2
Unknown1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT04052516Phase 2CompletedPrimary
A Phase 2b Study of Icosabutate in Fatty Liver Disease
NCT04065841Phase 2TerminatedPrimary
Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis.
NCT02548351Phase 3TerminatedPrimary
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment
NCT04880187Phase 2UnknownPrimary
Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis
NCT02098317Phase 3Completed
DHA and Vitamin D in Children With Biopsy-proven NAFLD
Showing all 5 trials